New Data shows SGLT2 Inhibitors May be effective in preventing Kidney Failure

New Data shows SGLT2 Inhibitors May be effective in preventing Kidney Failure

New data presented at the American Society of Nephrology meeting in San Diego last November offers new hope to people with diabetes at risk of kidney disease and kidney failure. They suggest a new class of glucose-lowering agents, sodium glucose co-transporter type 2 (SGLT2) inhibitors, may be effective in preventing kidney failure. This data has […]

Read More

November 27th, 2016

Lowering blood pressure to decrease risk of cardiovascular events

Globally, there are millions of people that could benefit from an intensive lowering of blood pressure (BP). An individual with lower BP decreases their chances of suffering from any cardiovascular events such as: stroke, heart disease or heart attacks. A new study shows that lowering blood pressure to less than 140 mm Hg, the current […]

Read More

November 21st, 2016

Bad news for saxagliptin?

Recently, the FDA said it will review possible heart risks associated with saxagliptin, a widely used diabetes drug.

Read More

February 13th, 2014

Lessons from the EVOLVE study

Cinacalcet is a drug that lowers levels of parathyroid hormone, a factor that is increased in almost all people with kidney failure and has been linked to an increased risk of fracture, cardiovascular events and death. It has been hoped that by reducing parathyroid hormone with cinacalcet, the risk of these clinical events will also […]

Read More

August 6th, 2013

required
required
required
required
I wish to subscribe to George Clinical communications.
required

Add George Clinical to your network